Holen Sie sich die Stockscreener-App
1.07
4.90%
0.05
Schlusskurs vom Vortag:
$1.02
Offen:
$1.05
24-Stunden-Volumen:
22.92M
Relative Volume:
5.37
Marktkapitalisierung:
$287.04M
Einnahmen:
$232.40M
Nettoeinkommen (Verlust:
$-20.51M
KGV:
-13.88
EPS:
-0.0771
Netto-Cashflow:
$60.04M
1W Leistung:
+18.97%
1M Leistung:
+5.94%
6M Leistung:
-35.93%
1J Leistung:
-69.94%
1-Tages-Spanne:
$0.996
$1.08
1-Wochen-Bereich:
$0.8838
$1.08
52-Wochen-Spanne:
$0.8227
$4.0787
Akebia Therapeutics Inc Stock (AKBA) Company Profile
Firmenname
Akebia Therapeutics Inc
Sektor
Telefon
617-871-2098
Adresse
245 FIRST STREET, CAMBRIDGE, MA
Compare AKBA vs TAK, HLN, TEVA, ZTS, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AKBA
Akebia Therapeutics Inc
|
1.07 | 287.04M | 232.40M | -20.51M | 60.04M | -0.0771 |
TAK
Takeda Pharmaceutical Co Adr
|
15.63 | 49.39B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
8.96 | 39.55B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.48 | 36.66B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
78.71 | 33.00B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
536.59 | 22.78B | 3.17B | 1.29B | 1.01B | 27.09 |
Akebia Therapeutics Inc Stock (AKBA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-04 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-04-28 | Eingeleitet | Leerink Partners | Outperform |
| 2025-04-01 | Eingeleitet | Jefferies | Buy |
| 2023-11-29 | Fortgesetzt | BTIG Research | Buy |
| 2023-08-28 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2023-05-31 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-03-31 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2022-03-31 | Herabstufung | Mizuho | Buy → Neutral |
| 2022-03-31 | Herabstufung | Needham | Buy → Hold |
| 2022-03-31 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-03-08 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-01-29 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2019-11-14 | Bestätigt | Needham | Buy |
| 2019-08-06 | Bestätigt | H.C. Wainwright | Buy |
| 2019-07-11 | Bestätigt | H.C. Wainwright | Buy |
| 2019-05-02 | Eingeleitet | JP Morgan | Overweight |
| 2019-03-20 | Eingeleitet | Citigroup | Neutral |
| 2018-09-07 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2018-08-10 | Bestätigt | Needham | Buy |
| 2018-06-06 | Bestätigt | H.C. Wainwright | Buy |
| 2017-12-19 | Eingeleitet | Piper Jaffray | Overweight |
| 2017-12-07 | Eingeleitet | BTIG Research | Buy |
| 2017-09-15 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2017-07-10 | Bestätigt | H.C. Wainwright | Buy |
| 2017-04-27 | Bestätigt | H.C. Wainwright | Buy |
| 2017-04-27 | Bestätigt | Needham | Buy |
| 2016-12-27 | Bestätigt | H.C. Wainwright | Buy |
| 2016-12-20 | Bestätigt | JMP Securities | Mkt Outperform |
| 2016-11-15 | Eingeleitet | Aegis Capital | Buy |
| 2016-09-29 | Eingeleitet | Brean Capital | Buy |
| 2016-03-16 | Bestätigt | Needham | Buy |
| 2016-01-21 | Eingeleitet | Credit Suisse | Neutral |
Alle ansehen
Akebia Therapeutics Inc Aktie (AKBA) Neueste Nachrichten
Akebia Therapeutics Inc (AKBA) Institutional Confidence - TradingKey
Akebia Therapeutics Inc (AKBA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
AKBA Shares Rise On Clinical Pipeline Optimism As Anemia Drug Gains Traction - Stocktwits
Akebia Therapeutics Inc (AKBA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Akebia Therapeutics Inc (AKBA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Akebia Therapeutics Inc (AKBA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Akebia Therapeutics (AKBA) AGM 2026 Summary - Quartr
AKBA: All proposals passed, including director elections and share authorization increase - TradingView
Akebia Therapeutics Inc (AKBA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
AKBA: All proposals, including director elections and share increases, were approved by stockholders - TradingView
Akebia Therapeutics Inc Annual Shareholders Meeting Transcript - GuruFocus
Akebia Therapeutics Inc (AKBA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Akebia Therapeutics Inc (AKBA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Akebia Therapeutics Inc (AKBA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Akebia Therapeutics sees Vafseo uptake rising as access and pipeline milestones near - MSN
Akebia Strengthens Patent Portfolio with New Grant for Vafseo (A - GuruFocus
Akebia receives new patent, extension eligibility for Vafseo - Investing.com
Akebia receives new patent, extension eligibility for Vafseo By Investing.com - Investing.com South Africa
Akebia Therapeutics Secures New Patent Covering Dosing Regimen for Chronic Kidney Disease - marketscreener.com
Akebia Therapeutics Announces New Patent and Patent Extension Eligibility for Vafseo® (vadadustat) Strengthening Intellectual Property Portfolio - Quiver Quantitative
Akebia Therapeutics Strengthens Vafseo® (vadadustat) Patent Portfolio - GlobeNewswire
Akebia’s Vafseo gains traction as $106B pharma M&A reshapes sector - MSN
Akebia Therapeutics Sees Vafseo Uptake Rising as Access and Pipeline Milestones Near - MarketBeat
AKBA: Vafseo growth accelerates, pipeline advances, and broad access expected post-2026 - TradingView
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
AKBA Stock Price, Quote & Chart | AKEBIA THERAPEUTICS INC (NASDAQ:AKBA) - ChartMill
Akebia Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference - The Manila Times
Kidney disease-focused Akebia to present at NY healthcare conference - Stock Titan
AKBA Q1 2026 Earnings: EPS Misses Estimates Amid Operational DevelopmentsEarnings Cycle Report - thelegaladvocate.com
AKBA Q1 2026 Earnings: EPS Misses Estimates as Stock Holds SteadyEarnings Surprise Stocks - thelegaladvocate.com
Akebia Therapeutics (AKBA) Edges Higher at $1.04 – Key Levels in FocusFair Value Gap - thelegaladvocate.com
Promising Penny Stocks To Consider In May 2026 - Yahoo Finance
Akebia Therapeutics Inc. (AKBA) Q1 2026 Earnings: EPS Misses Estimates Slightly, Stock UnchangedQuarterly Profit Report - thelegaladvocate.com
AKBA Technical Analysis & Stock Price Forecast - Intellectia AI
Akebia Therapeutics (AKBA) Holds Steady at $1.02 as Stock Consolidates Near Key SupportMomentum Stock Picks - newsline.com
Is the options market predicting a spike in Akebia Therapeutics stock? - MSN
Akebia plunges 20% on muted Q1 print - MSN
Number of shareholders of Akebia Therapeutics, Inc. – NASDAQ:AKBA - TradingView
Earnings call transcript: Akebia Therapeutics Q1 2026 reports EPS miss, stock falls - Investing.com Canada
Korsana deal and cash crunch reshape Cyclerion (NASDAQ: CYCN) outlook - Stock Titan
State Street (AKBA) reports 11.6M-share, 4.3% stake in Akebia - Stock Titan
HC Wainwright Issues Negative Estimate for AKBA Earnings - MarketBeat
TradingKey - TradingKey
Akebia outlines phase II FSGS study of up to ~60 patients as Vafseo reaches nearly 7,500 patients - MSN
Finanzdaten der Akebia Therapeutics Inc-Aktie (AKBA)
Umsatz
Nettogewinn
Free Cashflow
ENV
11.23%
0.45%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):